

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-33. (Canceled)

34. (New) An expression vector comprising a nucleotide sequence encoding non-human 5T4 antigen.

35. (New) The expression vector according to claim 34, wherein said non-human 5T4 antigen is murine 5T4 antigen.

36. (New) The expression vector according to claim 34, wherein said non-human 5T4 antigen is canine 5T4 antigen.

37. (New) An expression vector comprising a nucleotide sequence encoding modified 5T4 antigen, wherein said modified 5T4 antigen is capable of inducing an antitumor immunotherapeutic response in a subject.

38. (New) The expression vector according to claim 37, wherein said modified 5T4 antigen is human modified 5T4 antigen.

39. (New) The expression vector according to claim 37, wherein said antitumor immunotherapeutic response is a CTL response or an antibody response.

40. (New) The expression vector according to claim 37, wherein said modified 5T4 antigen comprises a peptide epitope of 5T4 antigen.

41. (New) The expression vector according to claim 40, wherein said modified 5T4 antigen comprises a peptide sequence selected from SEQ ID NOS: 5-17.

42. (New) The expression vector according to claim 40, wherein said modified 5T4 antigen comprises a peptide sequence selected from SEQ ID NOS: 18-27.

43. (New) A pair of vectors for priming and boosting an immune response to 5T4 antigen in a subject, said pair of vectors comprising a first vector which is the vector according to claim 34 and a second vector comprising a nucleotide sequence encoding 5T4 antigen, wherein said second vector is a poxvirus vector.

44. (New) The pair of vectors according to claim 43, wherein said first vector is a poxvirus vector.

45. (New) The pair of vectors according to claim 43, wherein said first vector is MVA.

46. (New) The pair of vectors according to claim 43, wherein said second vector is MVA.

47. (New) The pair of vectors according to claim 43, wherein said first vector comprises a nucleotide sequence encoding canine 5T4 antigen.

48. (New) A pair of vectors for priming and boosting an immune response to 5T4 antigen in a subject, said pair of vectors comprising a first vector which is the vector according to claim 37 and a second vector comprising a nucleotide sequence encoding 5T4 antigen, wherein said second vector is a poxvirus vector.

49. (New) The pair of vectors according to claim 48, wherein said first vector is a poxvirus vector.

50. (New) The pair of vectors according to claim 48, wherein said first vector is MVA.

51. (New) The pair of vectors according to claim 48, wherein said second vector is MVA.

52. (New) The pair of vectors according to claim 48, wherein said first vector comprises a nucleotide sequence encoding modified human 5T4 antigen.

53. (New) The pair of vectors according to claim 52, wherein said modified human 5T4 antigen comprises an HLA CTL peptide epitope of 5T4 antigen.